CORRECTION

Open Access

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Tahereh Javaheri^{1,2}, Zahra Kazemi^{3,4}, Jan Pencik^{1,3,5}, Ha T. T. Pham^{1,2}, Maximilian Kauer⁶, Rahil Noorizadeh^{1,2}, Barbara Sax¹, Harini Nivarthi^{1,7}, Michaela Schleder^{1,3,5}, Barbara Maurer^{1,2}, Maximilian Hofbauer¹, Dave N. T. Aryee^{6,8}, Marc Wiedner^{1,7}, Eleni M. Tomazou⁶, Malcolm Logan⁹, Christine Hartmann¹⁰, Jan P. Tuckermann¹¹, Lukas Kenner^{1,3,5,12}, Mario Mikula^{3,13}, Helmut Dolznig^{3,13}, Aykut Üren¹⁴, Günther H. Richter¹⁵, Florian Grebien¹, Heinrich Kovar^{6,8} and Richard Moriggl^{1,2,3}

Correction to: *Cell Death and Disease* (2016) 7, e2419; <https://doi.org/10.1038/cddis.2016.268>, Published online 13 October 2016.

Since the publication of the article, the authors became aware that Fig. 6a, d contained errors in the bands and loading controls. The newly compiled Fig. 6a, d is given below.

The authors apologise for any inconvenience caused.

Published online: 23 July 2018

Correspondence: Richard Moriggl (richard.moriggl@bcr.lbg.ac.at)

¹Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

²Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria

³Medical University of Vienna, Vienna, Austria

⁴Center of Physiology and Pharmacology, Vienna, Austria

⁵Clinical Institute of Pathology, Vienna, Austria

⁶Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria

⁷CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

⁸Department of Pediatrics, Medical University of Vienna, Vienna, Austria

⁹Randall Division of Cell and Molecular Biophysics, King's College London, London, UK

¹⁰Department of Bone and Skeletal Research, Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany

¹¹Institute of General Zoology and Endocrinology, University of Ulm, Ulm, Germany

¹²University of Veterinary Medicine, Vienna, Austria

¹³Institute of Medical Genetics, Vienna, Austria

¹⁴Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, USA

¹⁵Children's Cancer Research Centre and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Fig. 6 Knockdown of Mcl1 or Cdk4-induced cell cycle arrest and inhibited ES cell proliferation. **a** Mcl1 and Cdk4 siRNA analysis and expression check in murine and human ES cell lines resulted in upregulation of total RB and lower amount of pS780-RB. **b** Colony-forming assay in Matrigel displayed reduced clonogenic potency of EF-dependent cell lines after knockdown of Mcl1 or Cdk4 by siRNA treatment. **c** Cell cycle analysis of Mcl1 or Cdk4 siRNA treatment displayed enhanced G1 arrest. **d** In vitro growth inhibition of mouse and human EF-dependent cell lines by Palbociclib as well as the combinatorial treatment of Palbociclib and Obatoclax in triplicate. Cells were treated with inhibitors at the indicated concentration for 24 h. **e** CDK4/6 inhibition by Palbociclib displayed similar results as seen in the CDK4 siRNA assay